RAMUCIRUMAB IS A VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 ANTAGONIST THAT SPECIFICALLY BINDS VEGF RECEPTOR 2 AND BLOCKS BINDING OF VEGFR LIGANDS, VEGF-A, VEGF-C, AND VEGF-D. AS A RESULT, RAMUCIRUMAB INHIBITS LIGANDSTIMULATED ACTIVATION OF VEGF RECEPTOR 2, THEREBY INHIBITING LIGAND-INDUCED PROLIFERATION, AND MIGRATION OF HUMAN ENDOTHELIAL CELLS. RAMUCIRUMAB INHIBITED ANGIOGENESIS IN AN IN VIVO ANIMAL MODEL.